European Commission approves Mycapssa® for the treatment of Acromegaly Mycapssa® will be the first and only oral somatostatin analog approved in the EU Approval based on MPOWERED Phase 3. | December 5, 2022
Respiratory illnesses are running rampant among children, resulting in hospital visits and admissions at far higher rates than normal for this time of year, according to fresh data from hospitals across Ontario.
Amryt Reports Q3 2022 Financial and Operational Results streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Amryt (AMYT) Announces Publication of Results from Amryt's EASE Phase 3 Trial in Epidermolysis Bullosa streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The British Journal of Dermatology Publishes Results from Amryt’s EASE Phase 3 Trial in Epidermolysis Bullosa DUBLIN, Ireland, and Boston MA, October 25,.